EP0057

DRUG3 trials

Sponsors

National Cancer Institute (NCI), Ellipses Pharma

Conditions

Gastric CancerLung NeoplasmsOvarian CancerProstate CancerSmall Cell Lung CancerSmall-cell Lung CancerUrothelial CancerUrothelial Carcinoma

Phase 1

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

CompletedNCT02769962

National Cancer Institute (NCI)Lung Neoplasms, Prostate Cancer, Small Cell Lung Cancer +2

Start: 2016-05-09End: 2025-03-04Updated: 2025-07-28

Phase 2

EP0057 in Combination With Olaparib in Advanced Ovarian Cancer

CompletedNCT04669002

Ellipses PharmaOvarian Cancer

Start: 2020-12-14End: 2023-05-05Updated: 2023-08-02

EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer

WithdrawnNCT05411679

Ellipses PharmaGastric Cancer, Small-cell Lung Cancer

Start: 2023-04-30End: 2024-12-31Updated: 2023-06-12

Related Papers

Tumor-targeted top1 inhibitor delivery with optimized parp inhibition in advanced solid tumors: a phase i trial of gapped scheduling.

2025-10-27

Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors

Cancer Chemotherapy and Pharmacology2020-09-0818 citations

Measurement of NLG207 (formerly CRLX101) nanoparticle-bound and released camptothecin in human plasma.

2019-12-2718 citations

CRLX101 plus olaparib in patients with metastatic castration-resistant prostate cancer.

Journal of Clinical Oncology2018-05-202 citations